Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Martz L. (2009) Designer Lipocalins. SciBX 2(28) 8-9. Kim, H.J., Eichinger, A., Skerra A. (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc. 131(10):3565-76.
Key Takeaway: The article references two scientific works related to designer lipocalins and their applications in recognizing lanthanide(III) chelate complexes. It provides a brief overview of the research but lacks detailed insights or specific findings. The text appears to be a placeholder without substantial content.
Price reaction · baseline $22.05 (2025-06-20 close) · hit pre-market · 6 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita